7 results about "Early hcc" patented technology

The application belongs to the technical field of medical detection, and discloses a biomarker for diagnosing hepatocellular carcinoma and application thereof. The biomarker comprises a combination of coding nucleic acids of alpha-1-microglobulin, vitronectin, apolipoprotein A1, fibrinogen gamma chain, fibrinogen alpha chain and albumin; and the coding nucleic acids comprise mRNA or cDNA. The application purifies CD147 positive extracellular vesicles from plasma, and performs PCR detection on mRNA of hepatocellular carcinoma biomarkers carried in the extracellular vesicles. A HCC Score diagnosis model is constructed based on detection results of the biomarkers, and has high diagnostic sensitivity and specificity for hepatocellular carcinoma, has great potential in screening of early hepatocellular carcinoma, and has important practical significance for early diagnosis of hepatocellular carcinoma.

The application provides a three-differentiated methylation marker composition for detecting liver cancer / early liver cancer and application thereof, and belongs to the technical field of biological detection. The kit contains three DNA methylation markers, and the three-marker composition is significantly related to liver cancer. Through the combined results of the methylation levels of the three markers, the doctor can make a judgment on whether early liver cancer occurs. More than 70% of the samples used in the development of the kit reagent are early liver cancer samples (stage I or stage II), which is expected to improve the discovery rate of early liver cancer in the high-risk population of liver cancer in China, realize early discovery and early treatment, reduce the incidence and mortality of primary hepatocellular carcinoma, and reduce the pressure on individuals and social medical insurance.

The invention provides a marker composition for liver cancer detection, a liver cancer detection kit and a liver cancer detection device, and relates to the technical field of biology, and the marker composition comprises a DNA methylation marker positioned on at least one of a DAB2IP gene, a TSPYL5 gene and a ZNF783 gene. The marker composition has good sensitivity and specificity in liver cancer detection, and provides a new strategy and approach for screening and diagnosis of early liver cancer.

The invention relates to the technical field of medical imaging omics analysis, and discloses an early-stage liver cancer postoperative recurrence prediction model and method based on imaging omics phenotypes, and the method comprises the following steps: data collection and preprocessing, feature screening and standardization, model construction, model verification and risk layering. The data acquisition and preprocessing is to obtain preoperative enhanced CT image data and clinical information of an early-stage hepatocellular carcinoma (HCC) patient meeting the agralan standard, and the clinical information comprises serum alpha fetoprotein (AFP) level and tumor number. According to the image omics phenotype-based early liver cancer postoperative recurrence prediction model and method, pre-operation and post-operation dual models are constructed by integrating pre-operation enhanced CT image omics characteristics (including first-order statistics, texture and wavelet characteristics), clinical parameters (such as serum alpha fetoprotein and tumor number) and post-operation pathological variables (such as microvascular invasion and satellite nodules).

The invention discloses a liver / mitochondria dual-targeting carboxylesterase fluorescent probe as well as a preparation method and application thereof, and belongs to the technical field of medicines. The probe is a compound LDM-CA, has the liver and mitochondria dual-targeting characteristic, and shows high selectivity, sensitivity and strong binding affinity to CEs. In-vitro cell experiments show that the LDM-CA has excellent mitochondrial targeting ability in the HCC cells and specific fluorescence opening response to CEs in the cells, and can clearly distinguish the HCC cells from normal liver cells or non-liver cancer cells. In-vivo imaging of a mouse model shows that no matter in-tumor injection or intravenous injection, the LDM-CA can effectively visualize the HCC tumor and draw the edge of the tumor, has the prospect of serving as a powerful molecular tool for early HCC diagnosis and image-guided surgery, and also provides a valuable means for studying the action of mitochondrial CEs activity in HCC pathogenesis at the subcellular level.

The invention discloses a preparation method and application of an MCM complex for early-stage liver cancer prognosis judgment, and relates to the technical field of proteomics and clinical detection.The preparation method comprises the steps that para-carcinoma tissue of an early-stage hepatocellular carcinoma patient is obtained; performing protein extraction and enzymolysis on the para-carcinoma tissue to obtain a peptide fragment mixture; carrying out quantitative analysis on the peptide fragment mixture by adopting a mass spectrum technology in a data-dependent acquisition mode to obtain relative abundance of six proteins, namely MCM2, MCM3, MCM4, MCM5, MCM6 and MCM7; standardizing the relative abundance and substituting the standardized relative abundance into a preset discrimination formula to calculate a combined score; according to a comparison result of the combined score and a threshold value 3.659, the postoperative recurrence and metastasis risk level of the patient is judged; by means of the technical scheme, it is revealed that the MCM2-7 protein expression combination in the para-carcinoma tissue can serve as an independent prognostic marker for postoperative recurrence and metastasis of early hepatocellular carcinoma (BCLC 0 / A stage), and the limitation of traditional prognostic evaluation depending on tumor tissue is broken through.

A marker, kit, and system for screening or diagnosis of early-stage liver cancer, and a use. The marker comprises any one of AK2, DCTN2, DKK4, IFNGR1, TIMM10 or Galectin 4 protein, and a biomarker panel comprises any combination of AK2, DCTN2, DKK4, IFNGR1, TIMM10 or Galectin 4 protein. A model construction method comprises the following steps: S1, determining a training set, test set samples, and verification set samples, which each comprises healthy individual samples, liver cirrhosis patient samples, and liver cancer patient samples; S2, determining a protein biomarker / biomarker panel and a component weight; S3, using the training set and the test set samples to train a classification algorithm; S4, taking a Youden's index as an optimal threshold for distinguishing liver cancer and non-liver cancer individuals, and taking a Youden's index as an optimal threshold for distinguishing liver cirrhosis and extremely-early-stage liver cancer individuals; and S5, using the verification set samples to evaluate and optimize the performance of a classification algorithm model. The marker can achieve efficient and sensitive screening or diagnosis of early-stage liver cancer.